ImmuCell Corporation (NASDAQ:ICCC) Short Interest Down 49.5% in December

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 7,780 shares, a decrease of 49.5% from the December 15th total of 15,418 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 44,325 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 44,325 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC grew its stake in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 at the end of the most recent reporting period. 13.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell presently has a consensus rating of “Sell”.

ImmuCell Trading Down 4.2%

NASDAQ:ICCC traded down $0.28 during mid-day trading on Friday, hitting $6.36. 40,911 shares of the stock traded hands, compared to its average volume of 38,308. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $57.56 million, a price-to-earnings ratio of 24.46 and a beta of 0.18. ImmuCell has a 52 week low of $4.28 and a 52 week high of $7.60. The firm’s 50 day moving average is $5.75 and its two-hundred day moving average is $6.12.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The business had revenue of $5.51 million during the quarter.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.